<DOC>
	<DOCNO>NCT01764776</DOCNO>
	<brief_summary>This study evaluate pharmacokinetics safety 800 mg LDE225 subject impaired hepatic function healthy subject normal hepatic function .</brief_summary>
	<brief_title>Effect Hepatic Impairment LDE225..</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria ( group ) : Male sterile postmenopausal female age ≥18 ≤70 year old . Normal Vital sign Inclusion ( group mild , moderate severe hepatic impairment ) : Subjects confirm cirrhosis Exclusion ( group ) : Woman childbearing potential pregnant lactating female male use condom Risk factor torsades de pointes Clinically significant cardiovascular disease severe uncontrolled medical condition Smokers consume great 10 cigarette equivalent nicotine containing product per day . Use investigational drug ( i.e . participation clinical investigation ) Exclusion moderate , mild severe group : Symptoms history encephalopathy Clinical evidence severe ascites</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>LDE225</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>PK</keyword>
	<keyword>Postmenopausal woman</keyword>
	<keyword>normal hepatic function</keyword>
	<keyword>mild hepatic impairment</keyword>
	<keyword>moderate hepatic impairment</keyword>
	<keyword>severe hepatic impairment</keyword>
</DOC>